Credits: IMDb
“I'm not great at the advice. Can I interest you in a sarcastic comment?”

This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.
Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.
Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.
However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.
Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”
In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.
There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.
Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.
Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.
If it was not his session, then how did he get ketamine?
Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.
Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.
Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.
Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”
Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.
Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.
He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.
Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”
The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”
The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”
Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.
Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.
He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.
Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”
Five arrests have been made in the case so far.
Credit: AI
Millions of bottles of over-the-counter cooling eye drops have been recalled across the United States after the US Food and Drug Administration (FDA) raised concerns that the products may not be sterile. Sterility issues raises the risk of eye infections significantly.
The FDA has classified the recall as a Class II recall. An FDA Class II recall for a product refers to the public health action that may cause temporary health problems, where the chance of serious harm is remote.
This recall covers nearly 12 million bottles of eight Rohto cooling eye drop products. The agency said the recall was initiated on July 14, due to a “lack of assurance of sterility” in the affected products.
The eye drops were manufactured in Vietnam and distributed nationwide by The Mentholatum Company.
The recent FDA recall includes several popular Rohto products, including:
The food and drugs regulatory body has warned consumers to stop using the recalled eye drops immediately and check the FDA’s recall notice for affected lot numbers and expiration dates.
Also read: FDA Recalls Popular Thyroid Medication: What Levothyroxine Users Need to Know
Unlike tablets or capsules, eye drops are applied directly onto the eye. The process has limited natural protection against harmful microorganisms.
When sterility cannot always be guaranteed, bacteria or fungi may contaminate the solution easily.
Using contaminated eye drops significantly increases the risk of eye irritation, painful infections, damage to the corneas and, in extreme cases, vision loss.
Although the FDA has not disclosed any confirmed adverse effects linked to this recall, it said the products were withdrawn from the market as a precaution because ophthalmic products must strictly remain sterile throughout their shelf life.
The agency classified the recall as Class II, meaning exposure could cause temporary or reversible health effects, while serious harm is mostly unlikely.
Also read: US FDA Approves New Blood Test To Screen For Colorectal Cancer
Commenting on previous FDA recalls, Dr Gary Novack, clinical professor in the Department of Ophthalmology and Vision Science at UC Davis, said, “For eye drops, that means strict sterility, ensuring products are free from microorganisms like bacteria.”
He also said that manufacturing facilities must maintain contamination-free conditions because medicines used in the eye bypass many of the body’s natural defence mechanisms.
Dr Jeffrey H. Ma, ophthalmologist at the UC Davis Eye Center, also advised patients not to use recalled products: “Drops that are not on the recall list should be safe to use. If you have any of the drops on the list, you should immediately throw them away.”
Health authorities recommend that people:
The latest recall comes after multiple eye drop recalls in recent years linked to manufacturing and sterility issues, highlighting growing scrutiny of ophthalmic products.
Credit: AP
US President is reportedly asking Secretary of the US Department of Health and Human Services Robert F. Kennedy Jr to make more efforts to cut childhood vaccines in America, according to a media report.
The 80-year-old US president hopes to make “alleviating autism” a component of his legacy, and told Kennedy that he wasn’t making enough cuts to the US vaccination schedule, the Wall Street Journal reported. The report, citing sources, said that Trump believes cutting down the number of recommended childhood vaccines may lead to a drop in autism rates in the country.
He, thus, expressed frustration with the slow pace of progress on the issue at a mid-June Oval Office meeting with Kennedy.
“Donald Trump has been anti-vaccine at least since 2015,” said Paul Offit, director of the Vaccine Education Center and an infectious diseases physician at Children’s Hospital of Philadelphia. At the Republican primary debate that year, Trump said that autism had gotten “totally out of control” and vaccines should be in “smaller doses over a longer period of time”.
Further, Trump reportedly also wants to break the combination vaccine for the measles, mumps, and rubella vaccination (MMR) into different shots, to reduce the risk of autism.
However, there has been no scientific evidence to prove that paring down the childhood vaccine schedule can reduce autism rates. Similarly, studies over the years have shown no connection between the MMR and autism.
Kennedy, last year, cancelled roughly $500 million in mRNA vaccine research grants and removed every single member of an immunization advisory panel.
But after White House aides told Kennedy that vaccine skepticism was less popular with voters, and they asked him to focus on more palatable topics, such as food reform, the Health Secretary has largely been mum on vaccines publicly. Trump’s recent urgency on the issue ignores his political advisers’ warnings.
Meanwhile, the US Centers for Disease Control and Prevention's (CDC) revised webpage on autism and vaccines is reigniting the debate over how health agencies should communicate scientific evidence.
The controversy was sparked by changes made to the CDC's autism webpage, which now states that the claim "vaccines do not cause autism" is "not an evidence-based claim" as studies have not ruled out every possible link between infant vaccines and autism.
The page also says the HHS is continuing to investigate the causes of autism.
The revised language represents a shift from the CDC's longstanding public messaging, which for years stated that extensive scientific research had found no causal relationship between vaccines and autism.
Republican Senator Bill Cassidy slammed the agency's messaging while continuing to defend the overwhelming scientific evidence that vaccines do not cause autism.
The changes have also drawn criticism from scientists, physicians, and lawmakers who fear they could weaken public confidence in routine childhood immunization.
Despite the debate surrounding the CDC webpage, the broader scientific consensus has not changed. Large studies conducted over several decades in multiple countries have consistently found no evidence that routine childhood vaccines cause autism.
Major medical organizations continue to support vaccination as one of the safest and most effective public health interventions.
Health experts have also warned that ambiguous or conflicting public health messaging could further affect vaccine confidence at a time when the United States is experiencing its highest number of measles cases in more than three decades, largely driven by declining childhood vaccination rates.
The controversy highlights the growing tension between political oversight and scientific communication within U.S. public health agencies.
For public health experts, the concern extends beyond a single webpage. They argue that how government agencies present scientific evidence can directly influence vaccine confidence, healthcare decisions, and efforts to prevent outbreaks of vaccine-preventable diseases.
Credit: AI
A new study suggests that nearly one in three adults in the United States could benefit from blood pressure-lowering medication under the latest treatment guidelines.
Yet millions who qualify are either not taking medication or have blood pressure that remains above recommended targets, highlighting a major gap in hypertension care.
The findings, published in JAMA, analysed data from the U.S. National Health and Nutrition Examination Survey (NHANES) collected between 2021 and 2023.
Researchers evaluated how the updated 2025 American Heart Association (AHA) and American College of Cardiology (ACC) blood pressure guidelines would affect treatment eligibility.
According to the researchers, an estimated 34 million U.S. adults, roughly one in three, meet the criteria for blood pressure medication but are not currently taking it.
Nearly 19 million of them have blood pressure readings of 140/90 mmHg or higher, placing them at increased risk of heart attack, stroke, kidney disease, and dementia if left untreated.
The study also found that almost 80% of adults with hypertension have blood pressure levels above the recommended treatment goal of less than 130/80 mmHg.
Also read: Not Just The Heart, Obesity In Midlife Could Be Just As Harmful To The Brain: Study
Researchers observed that many adults with high blood pressure were not taking any antihypertensive medication, despite being eligible under current guidelines.
Among those who were not receiving treatment, about two-thirds had blood pressure values within 10 mmHg of the recommended target.
The observation suggested that a combination of medication and lifestyle changes could help many get their readings down.
On the other hand, people who were already taking medication often had blood pressure levels that remained well above target, indicating that medication may need to be intensified.
The authors wrote, “Many could potentially achieve blood pressure control with initiation of antihypertensive medication and lifestyle modification.”
They further noted, “These findings highlight a large gap in hypertension control that implementation of the 2025 AHA/ACC blood pressure guideline recommendations could address.”
High blood pressure is often called the “silent killer” because it usually causes no symptoms while quietly damaging blood vessels and vital organs over time.
According to the U.S. Centers for Disease Control and Prevention (CDC), uncontrolled hypertension is a major contributor to heart disease and stroke, two of the leading causes of death in the country.
Researchers also pointed out that more than 80% of adults with uncontrolled blood pressure had health insurance and a regular place for medical care, suggesting that access alone does not fully explain why treatment goals are not being met.
The updated AHA/ACC guidelines emphasise that treatment should not rely on medication alone. Doctors recommend:
As hypertension continues to affect millions, researchers say earlier diagnosis, timely treatment, and sustained lifestyle changes could substantially reduce the burden of cardiovascular disease and improve long-term health outcomes.
© 2024 Bennett, Coleman & Company Limited